Catestatin

A New Hypertension / Stress / Insomnia / Cancer Biomarker

acts as a potent endogenous nicotinic cholinergic antagonist to inhibit catecholamine release.
induces release of histamine from mast cells.
displays potent antimicrobial activity

Human Catestatin RIA Kit (RK-053-27)

Rat(RK-053-28) and Mouse(RK-053-29) Catestatin RIA Kits

Human(EK-053-27) and Rat(EK-053-29) Catestatin EIA Kits

Human(FEK-053-27) and Rat(FEK-053-29) Catestatin Fluorescent EIA Kits

Mapping in Human Adrenal Medullary Tissue (H-053-27 / H-053-29)

Protocol for antibody staining

Tissue Sample	Human adrenal medullary
Fixative	10% formalin
Embedding	Paraffin
Negative Control	No primary antibody
Pretreatment	N/A
Blocking	3% H₂O₂, 2% Normal Goat Serum
Primary Antibody	Rabbit anti-Catestatin (Human) Antibody (Cat. No.: H-053-27)
Optimal Dilution	1: 500
Secondary Antibody	Goat Anti-Rabbit IgG, Biotinylated (1:400), 30 min
Amplification	Streptavidin-HRP (Vector), 1:400, 30 min
Detection System	HRP
Substrate	DAB (Sigma), 3 min
Counterstained	Hematoxylin, 30 sec

Tissue Sample	Human adrenal medullary tissues
Fixative	10% formalin
Embedding	Paraffin
Negative Control	No primary antibody
Pretreatment	N/A
Blocking	3% H₂O₂, 2% Normal Goat Serum
Primary Antibody	Rabbit Anti-Catestatin (Rat) Antibody (Cat. No.: H-053-29)
Optimal Dilution	1: 500
Secondary Antibody	Goat Anti-Rabbit IgG, Biotinylated (1:400), 30 min
Amplification	Streptavidin-HRP (Vector), 1:400, 30 min
Detection System	HRP
Substrate	DAB (Sigma), 3 min
Counterstained	Hematoxylin, 30 sec

Mapping in Human Pancreas Tissue (H-053-27 / H-053-28)

Protocol for antibody staining

Tissue Sample	Human pancreas tissues
Fixative	10% formalin
Embedding	Paraffin
Negative Control	No primary antibody
Pretreatment	N/A
Blocking	3% H₂O₂, 2% Normal Goat Serum
Primary Antibody	Rabbit Anti-Catestatin (Mouse) Antibody (Cat. No.: H-053-28)
Optimal Dilution	1: 500
Secondary Antibody	Goat Anti-Rabbit IgG, Biotinylated (1:400), 30 min
Amplification	Streptavidin-HRP (Vector), 1:400, 30 min
Detection System	HRP
Substrate	DAB (Sigma), 3 min
Counterstained	Hematoxylin, 30 sec

Tissue Sample	Human pancreas tissues
Fixative	10% formalin
Embedding	Paraffin
Negative Control	No primary antibody
Pretreatment	N/A
Blocking	3% H₂O₂, 2% Normal Goat Serum
Primary Antibody	Rabbit anti-Catestatin (Human) Antibody (Cat. No.: H-053-27)
Optimal Dilution	1: 500
Secondary Antibody	Goat Anti-Rabbit IgG, Biotinylated (1:400), 30 min
Amplification	Streptavidin-HRP (Vector), 1:400, 30 min
Detection System	HRP
Substrate	DAB (Sigma), 3 min
Counterstained	Hematoxylin, 30 sec

Western Blot Analysis of Chromogranin A in Rat Kidney Tissue (H-053-27)

Chromogranin A: a surprising link between granule biogenesis and hypertension

cgA

Relationship of CHGA-mediated dense-core secretory granule (DCG) biogenesis, catecholamine (CA) secretion, and its subsequent inhibition by the CHGA-derived peptide catestatin in the maintenance of blood pressure by the adrenal gland. CHGA, as a full-length molecule, initiates dense-core secretory granule biogenesis at the trans-Golgi network of adrenal chromaffin cells. Current data suggests that CHGA enhances granule biogenesis by preventing posttranslational degradation of other granule proteins in the Golgi complex. In the cytoplasm, catecholamine is synthesized and transported into the dense-core secretory granules via vesicular monoamine transporters. Upon stimulation by acetylcholine (Ach), catecholamine is coreleased with CHGA and catestatin from the granules. Secreted catecholamine triggers cardiovascular target cells to augment blood flow. This sympathoadrenal activity is then antagonized by the action of catestatin on cholinergic receptors to inhibit catecholamine secretion. [Ca2+]i, intracellular calcium concentration.
Kim et al. J. Clin. Invest. 115:1711-1713 (2005)